Defining a standard set of patient-centered outcomes for men with localized prostate cancer

Neil E. Martin, Laura Massey, Caleb Stowell, Chris Bangma, Alberto Briganti, Anna Bill-Axelson, Michael Blute, James Catto, Ronald C. Chen, Anthony V. D'Amico, Günter Feick, John M. Fitzpatrick, Steven J. Frank, Michael Froehner, Mark Frydenberg, Adam Glaser, Markus Graefen, Daniel Hamstra, Adam Kibel, Nancy MendenhallKim Moretti, Jacob Ramon, Ian Roos, Howard Sandler, Francis J. Sullivan, David Swanson, Ashutosh Tewari, Andrew Vickers, Thomas Wiegel, Hartwig Huland

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment. Objective To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value. Design, setting, and participants We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices. Outcome measurements and statistical analysis The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set. Results and limitations We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons. Conclusions We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care. Patient summary Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.

Original languageEnglish
Pages (from-to)460-467
Number of pages8
JournalEuropean Urology
Volume67
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Prostatic Neoplasms
Telecommunications
Cost Control
Urinary Incontinence
Therapeutics
Registries
Comorbidity
Radiation
Neoplasm Metastasis
Delivery of Health Care
Recurrence
Survival
Health

Keywords

  • Outcome measurement
  • Patient-reported
  • Prostate cancer
  • Value

ASJC Scopus subject areas

  • Urology

Cite this

Martin, N. E., Massey, L., Stowell, C., Bangma, C., Briganti, A., Bill-Axelson, A., ... Huland, H. (2015). Defining a standard set of patient-centered outcomes for men with localized prostate cancer. European Urology, 67(3), 460-467. https://doi.org/10.1016/j.eururo.2014.08.075

Defining a standard set of patient-centered outcomes for men with localized prostate cancer. / Martin, Neil E.; Massey, Laura; Stowell, Caleb; Bangma, Chris; Briganti, Alberto; Bill-Axelson, Anna; Blute, Michael; Catto, James; Chen, Ronald C.; D'Amico, Anthony V.; Feick, Günter; Fitzpatrick, John M.; Frank, Steven J.; Froehner, Michael; Frydenberg, Mark; Glaser, Adam; Graefen, Markus; Hamstra, Daniel; Kibel, Adam; Mendenhall, Nancy; Moretti, Kim; Ramon, Jacob; Roos, Ian; Sandler, Howard; Sullivan, Francis J.; Swanson, David; Tewari, Ashutosh; Vickers, Andrew; Wiegel, Thomas; Huland, Hartwig.

In: European Urology, Vol. 67, No. 3, 01.03.2015, p. 460-467.

Research output: Contribution to journalArticle

Martin, NE, Massey, L, Stowell, C, Bangma, C, Briganti, A, Bill-Axelson, A, Blute, M, Catto, J, Chen, RC, D'Amico, AV, Feick, G, Fitzpatrick, JM, Frank, SJ, Froehner, M, Frydenberg, M, Glaser, A, Graefen, M, Hamstra, D, Kibel, A, Mendenhall, N, Moretti, K, Ramon, J, Roos, I, Sandler, H, Sullivan, FJ, Swanson, D, Tewari, A, Vickers, A, Wiegel, T & Huland, H 2015, 'Defining a standard set of patient-centered outcomes for men with localized prostate cancer', European Urology, vol. 67, no. 3, pp. 460-467. https://doi.org/10.1016/j.eururo.2014.08.075
Martin, Neil E. ; Massey, Laura ; Stowell, Caleb ; Bangma, Chris ; Briganti, Alberto ; Bill-Axelson, Anna ; Blute, Michael ; Catto, James ; Chen, Ronald C. ; D'Amico, Anthony V. ; Feick, Günter ; Fitzpatrick, John M. ; Frank, Steven J. ; Froehner, Michael ; Frydenberg, Mark ; Glaser, Adam ; Graefen, Markus ; Hamstra, Daniel ; Kibel, Adam ; Mendenhall, Nancy ; Moretti, Kim ; Ramon, Jacob ; Roos, Ian ; Sandler, Howard ; Sullivan, Francis J. ; Swanson, David ; Tewari, Ashutosh ; Vickers, Andrew ; Wiegel, Thomas ; Huland, Hartwig. / Defining a standard set of patient-centered outcomes for men with localized prostate cancer. In: European Urology. 2015 ; Vol. 67, No. 3. pp. 460-467.
@article{47200cf570eb4794a5089643456013b9,
title = "Defining a standard set of patient-centered outcomes for men with localized prostate cancer",
abstract = "Background Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment. Objective To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value. Design, setting, and participants We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices. Outcome measurements and statistical analysis The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set. Results and limitations We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons. Conclusions We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care. Patient summary Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.",
keywords = "Outcome measurement, Patient-reported, Prostate cancer, Value",
author = "Martin, {Neil E.} and Laura Massey and Caleb Stowell and Chris Bangma and Alberto Briganti and Anna Bill-Axelson and Michael Blute and James Catto and Chen, {Ronald C.} and D'Amico, {Anthony V.} and G{\"u}nter Feick and Fitzpatrick, {John M.} and Frank, {Steven J.} and Michael Froehner and Mark Frydenberg and Adam Glaser and Markus Graefen and Daniel Hamstra and Adam Kibel and Nancy Mendenhall and Kim Moretti and Jacob Ramon and Ian Roos and Howard Sandler and Sullivan, {Francis J.} and David Swanson and Ashutosh Tewari and Andrew Vickers and Thomas Wiegel and Hartwig Huland",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.eururo.2014.08.075",
language = "English",
volume = "67",
pages = "460--467",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Defining a standard set of patient-centered outcomes for men with localized prostate cancer

AU - Martin, Neil E.

AU - Massey, Laura

AU - Stowell, Caleb

AU - Bangma, Chris

AU - Briganti, Alberto

AU - Bill-Axelson, Anna

AU - Blute, Michael

AU - Catto, James

AU - Chen, Ronald C.

AU - D'Amico, Anthony V.

AU - Feick, Günter

AU - Fitzpatrick, John M.

AU - Frank, Steven J.

AU - Froehner, Michael

AU - Frydenberg, Mark

AU - Glaser, Adam

AU - Graefen, Markus

AU - Hamstra, Daniel

AU - Kibel, Adam

AU - Mendenhall, Nancy

AU - Moretti, Kim

AU - Ramon, Jacob

AU - Roos, Ian

AU - Sandler, Howard

AU - Sullivan, Francis J.

AU - Swanson, David

AU - Tewari, Ashutosh

AU - Vickers, Andrew

AU - Wiegel, Thomas

AU - Huland, Hartwig

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment. Objective To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value. Design, setting, and participants We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices. Outcome measurements and statistical analysis The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set. Results and limitations We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons. Conclusions We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care. Patient summary Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.

AB - Background Value-based health care has been proposed as a unifying force to drive improved outcomes and cost containment. Objective To develop a standard set of multidimensional patient-centered health outcomes for tracking, comparing, and improving localized prostate cancer (PCa) treatment value. Design, setting, and participants We convened an international working group of patients, registry experts, urologists, and radiation oncologists to review existing data and practices. Outcome measurements and statistical analysis The group defined a recommended standard set representing who should be tracked, what should be measured and at what time points, and what data are necessary to make meaningful comparisons. Using a modified Delphi method over a series of teleconferences, the group reached consensus for the Standard Set. Results and limitations We recommend that the Standard Set apply to men with newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or other methods. The Standard Set includes acute toxicities occurring within 6 mo of treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-reported domains of urinary incontinence and irritation, bowel symptoms, sexual symptoms, and hormonal symptoms are included, and the recommended measurement tool is the Expanded Prostate Cancer Index Composite Short Form. Disease control outcomes include overall, cause-specific, metastasis-free, and biochemical relapse-free survival. Baseline clinical, pathologic, and comorbidity information is included to improve the interpretability of comparisons. Conclusions We have defined a simple, easily implemented set of outcomes that we believe should be measured in all men with localized PCa as a crucial first step in improving the value of care. Patient summary Measuring, reporting, and comparing identical outcomes across treatments and treatment centers will provide patients and providers with information to make informed treatment decisions. We defined a set of outcomes that we recommend being tracked for every man being treated for localized prostate cancer.

KW - Outcome measurement

KW - Patient-reported

KW - Prostate cancer

KW - Value

UR - http://www.scopus.com/inward/record.url?scp=84961291675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961291675&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2014.08.075

DO - 10.1016/j.eururo.2014.08.075

M3 - Article

C2 - 25234359

AN - SCOPUS:84961291675

VL - 67

SP - 460

EP - 467

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -